Mark Cervi
Internal Medicine · Greenville, NCNPI 1700846672
Payments from drug & device makers
Across 309 payments — averaging $16.46 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$655
- Amgen$628
- GSK$454
- AbbVie$417
- Lilly USA, LLC$284
- Novo Nordisk$249
- plus $2K from 31 others
What the payments were for
- Food & beverage$5,066100%
- Education$200%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 31 | $655 |
| Amgen | 44 | $628 |
| GSK | 22 | $454 |
| AbbVie(2 entities) | 21 | $417 |
| Lilly USA, LLC | 20 | $284 |
| Novo Nordisk | 18 | $249 |
| Boehringer Ingelheim | 14 | $215 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 15 | $209 |
| Pfizer | 15 | $205 |
| Merck | 15 | $201 |
| Akcea Therapeutics, Inc. | 4 | $152 |
| Eisai Inc. | 8 | $117 |
| Boston Scientific | 6 | $115 |
| Regeneron Healthcare Solutions, Inc. | 6 | $113 |
| Esperion Therapeutics, Inc. | 7 | $111 |
| Novartis | 7 | $97 |
| Biohaven Pharmaceuticals, Inc. | 6 | $93 |
| Astellas Pharma US Inc | 5 | $81 |
| Kowa Pharmaceuticals America, Inc. | 6 | $75 |
| Grifols USA, LLC | 3 | $63 |
| Amarin Pharma, Inc. | 4 | $63 |
| Acerus Pharmaceuticals Corporation | 2 | $50 |
| Dynavax Technologies Corporation | 4 | $47 |
| Teva Pharmaceuticals USA, Inc. | 3 | $45 |
| Sanofi-aventis U.S. LLC | 3 | $43 |
| Arbor Pharmaceuticals, Inc. | 3 | $43 |
| Abbott | 2 | $39 |
| Gilead | 3 | $37 |
| Aytu Biopharma, Inc. | 2 | $36 |
| Clarus Therapeutics Inc. | 2 | $33 |
| Johnson & Johnson | 2 | $28 |
| Phadia US Inc. | 1 | $17 |
| Antares Pharma, Inc. | 1 | $16 |
| Dexcom, Inc. | 1 | $15 |
| Currax Pharmaceuticals LLC | 1 | $13 |
| Mylan Specialty L.p. | 1 | $13 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- FARXIGA$225
- TRELEGY ELLIPTA$124
- VRAYLAR$100
How this compares
$5,086 in reported general payments places this provider in the 85th percentile of 3,302 internal medicine providers in North Carolina.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Azithromycin | 11 | $71 |
Paid to pharmacies, not to this prescriber.
Other internal medicine in Greenville
- Manesh PatelDurham$27.2M
- Saad UsmaniCharlotte$16.2M
- Christina KennellyCharlotte$15.4M
- John RubinoRaleigh$13M
- Adam DevoreDurham$11.8M
- Krishnakumar UdayakumarDurham$11M
- Sylvia ShoffnerCary$7.1M
- Wayne HarperRaleigh$6.7M
- Joseph MoranStatesville$6.7M
- April SalamaDurham$6.5M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.